Optimum News Archives - Optimum Strategic Communications

Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

Client News

Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), … Continue reading “Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR”

By Optimum

Kiadis draws €20 million from bridge loan with Sanofi

Client News

Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) … Continue reading “Kiadis draws €20 million from bridge loan with Sanofi”

By Optimum

ConserV Bioscience and Lawrence Livermore National Laboratory to Collaborate on Development of Broad-spectrum Coronavirus Vaccine

Client News

ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines … Continue reading “ConserV Bioscience and Lawrence Livermore National Laboratory to Collaborate on Development of Broad-spectrum Coronavirus Vaccine”

By Optimum

Novo Seeds’ portfolio company, IO Biotech, completes oversubscribed EUR 127m Series B financing to accelerate clinical programs in oncology

Client News

Novo Seeds, the early-stage investment and company creation team of Novo Holdings, … Continue reading “Novo Seeds’ portfolio company, IO Biotech, completes oversubscribed EUR 127m Series B financing to accelerate clinical programs in oncology”

By Optimum

NEURAXPHARM LAUNCHES FIRST PRODUCT IN JAPAN

Client News

Neuraxpharm launches first product in Japan Launch of Buccolam® – market leading … Continue reading “NEURAXPHARM LAUNCHES FIRST PRODUCT IN JAPAN”

By Optimum

Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

Client News

Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing … Continue reading “Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer”

By Optimum

Versameb Announces Management Update

Client News

Dr Klaas Zuideveld appointed as Chief Executive Officer to accelerate the development … Continue reading “Versameb Announces Management Update”

By Optimum

Novo Holdings participates in BioGeneration Ventures IV Fund

Client News

Novo Ventures, the ventures arm of Novo Holdings, today announces its participation … Continue reading “Novo Holdings participates in BioGeneration Ventures IV Fund”

By Optimum

Turbine Raises EUR 5.7M to Advance Simulation-first Oncology Pipeline

Client News

Turbine, a company simulating cellular decision making to unlock novel oncology therapies, … Continue reading “Turbine Raises EUR 5.7M to Advance Simulation-first Oncology Pipeline”

By Optimum

Novo Seeds portfolio company CorWave raises EUR 35m for breakthrough heart pump

Client News

Novo Seeds, the early stage investment and company creation team of Novo … Continue reading “Novo Seeds portfolio company CorWave raises EUR 35m for breakthrough heart pump”

By Optimum

Destiny Pharma Update on the recently acquired NTCD-M3 programme

Client News

Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of … Continue reading “Destiny Pharma Update on the recently acquired NTCD-M3 programme”

By Optimum

Positive results show that C21 can become an important complement to COVID-19 vaccines

Client News

Gothenburg, December 21, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical … Continue reading “Positive results show that C21 can become an important complement to COVID-19 vaccines”

By Optimum

MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials

Client News

MinervaX, a privately held Danish biotechnology company developing a novel vaccine against … Continue reading “MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials”

By Optimum

REPAIR Impact Fund supports upsized MinervaX EUR 47.4m Series B financing to advance novel vaccine against Gr. B Streptococcus

Client News

Today the Novo Holdings REPAIR Impact Fund announces a further investment in … Continue reading “REPAIR Impact Fund supports upsized MinervaX EUR 47.4m Series B financing to advance novel vaccine against Gr. B Streptococcus”

By Optimum

Neuraxpharm establishes operations in the Republic of Ireland through the acquisition of Medinutrix

Client News

Neuraxpharm acquires Medinutrix Ltd to provide an immediate platform for the recently … Continue reading “Neuraxpharm establishes operations in the Republic of Ireland through the acquisition of Medinutrix”

By Optimum

Novo Holdings Creates New Rare Bleeding Disorder Company, Hemab

Client News

Funded through Novo Seeds’ company creation and building efforts Focus on rare … Continue reading “Novo Holdings Creates New Rare Bleeding Disorder Company, Hemab”

By Optimum

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Client News

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its … Continue reading “Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates”

By Optimum

The Novo Nordisk Foundation establishes BioInnovation Institute as an independent foundation

Client News

With continued positive development, The Novo Nordisk Foundation can provide up to … Continue reading “The Novo Nordisk Foundation establishes BioInnovation Institute as an independent foundation”

By Optimum

Futura provides US regulatory and commercial update

Client News

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura provides US regulatory and commercial update”

By Optimum